Risk Factors Associated With the Absence of CMV-specific Cellular Immune Response in the Early Post-transplant Period in Low-risk CMV-seropositive Kidney Transplant Recipients (PREDICOR)
The goal of this observational study is to identify risk factors associated with the absence of CMV-specific cellular immune response in low-risk CMV-seropositive kidney transplant recipients in the early post-transplant period. The participant population includes adult CMV-seropositive kidney transplant recipients who did not receive antithymocyte globulin (ATG) induction therapy and underwent QuantiFERON-CMV testing within the first 45 days after transplantation.
The main question it aims to answer is:
- Is it possible to predict which patients will fail to develop a CMV-specific cellular immune response before day 45 post-transplant in the absence of directly available immune assessment techniques?
Researchers will compare patients with reactive QuantiFERON-CMV results to patients with non-reactive or indeterminate results to identify factors associated with the absence of CMV-specific cellular immune response.
Participants will have retrospective clinical and laboratory data collected from medical records.
研究概览
地位
详细说明
Study Hypothesis: In the absence of available techniques to assess CMV-specific cellular immunity, it may be possible to predict which patients will fail to develop a CMV-specific cellular immune response before day 45 post-transplant.
Objective:
Primary objective:
- Derivation Cohort: To evaluate the risk factors associated with a non-reactive or indeterminate QF-CMV result before day 45 post-transplant in CMV-seropositive (R⁺) recipients who did not receive ATG prophylaxis.
- Validation Cohort: To validate these risk factors in an independent validation cohort.
Secondary Objectives:
- To confirm whether patients with a non-reactive or indeterminate QF-CMV result before day 45 post-transplant and without ATG induction develop a higher rate of clinically significant CMV infection compared with those with a reactive QF-CMV result during the first 6 months post-transplant.
- To confirm whether these same patients present a higher rate of viral replication during the first 6 months post-transplant.
Study Population: The study will include adult patients (>18 years) who are CMV-seropositive (R⁺), received a kidney transplant during the study period, did not receive ATG prophylaxis, and underwent QF-CMV testing on day 45 post-transplant (with a window period between day 30 and day 60 post-transplant).
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Córdoba、西班牙、14004
- Hospital Universitario Reina Sofia
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Age >18 years
- Kidney or pancreas-kidney transplant recipients with positive CMV serology
- QF-CMV test performed on day 45 post-transplant (window period between day 30 and day 60 post-transplant)
- CMV PCR testing performed at least every two weeks during the first three months post-transplant
Exclusion Criteria:
- HIV-infected patients
- Multivisceral transplant recipients
- Patients scheduled to receive universal prophylaxis despite having a reactive QF-CMV result
- Patients who received ATG induction therapy
- Less than 6 months of post-transplant follow-up
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
Derivation cohort
The first phase will identify clinical and immunological risk factors associated with a non-reactive or indeterminate QF-CMV test result performed before day 45 post-transplant.
|
|
Validation cohort
In the second phase, the risk factors identified in the derivation cohort will be tested in an independent cohort to validate their predictive value for the early absence of CMV-specific cellular immunity.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Risk factors associated with a non-reactive or indeterminate QF-CMV
大体时间:Between 15 and 45 days after kidney transplantation
|
Absence of CMV-specific cellular immune response assessed by early QuantiFERON-CMV testing
|
Between 15 and 45 days after kidney transplantation
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- FCO-PRE-2025-05
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.